WASHINGTON, January 30, 2007 /PRNewswire-USNewswire/ -- The federal Food and Drug Administration is too slow to approve new drugs and medical devices, according to a survey of orthopedic surgeons released today. A strong majority of the surgeons believe that FDA approval delays hinder hurt patients and hinder their practice of medicine. Eighty percent would also like to see the painkiller Vioxx, which was voluntarily withdrawn in 2004, available once again.
CEI General Counsel Sam Kazman stated, "In recent years FDA has been repeatedly attacked for approving allegedly defective therapies. But as this physician survey shows, the real threat to public health is that FDA's approval process is already too long. Any attempt to make it more stringent will only worsen this problem."
Join our conference call Q&A today with Sam Kazman and polling company President Kellyanne Conway
11:30 a.m. ET
Dial-in number: 1.866.409.4300, code 3312252
Among the highlights of the new survey are the following:
-- over three-quarters, 76%, believe FDA's approval process is too slow;
-- 60% believe FDA hinders their use of new therapies;
-- 73% believe FDA approval delays hurt patients;
-- 70% favor changing the law to give physicians access to unapproved
therapies if they carry a warning about their unapproved status;
-- 80% favor having Vioxx available again.
This is the sixth in a series of medical specialist surveys conducted by CEI, beginning with a 1995 poll of oncologists. These surveys have consistently found a high level of dissatisfaction with FDA's performance, though the newest poll shows an exceptionally negative view of the agency.
-- See the survey of orthopedic surgeons + side-by-side comparison of all
CEI medical specialty polls
Competitive Enterprise Institute (CEI) is a non-profit, non-partisan public policy group dedicated to the principles of free enterprise and limited government. For more information about CEI, please visit our website at http://www.cei.org
Contact: Christine Hall, 202-331-2258
CONTACT: Christine Hall of Competitive Enterprise Institute,+1-202-331-2258
Web site: http://www.cei.org/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
| Link to this page |  |
Printable Version |  |
Email Page |  |
Add to my drug list |
More Aclasta resources:
Zoledronic Acid - Includes detailed dosage instructions.
Hypercalcemia of Malignancy, Osteolytic Bone Lesions of Multiple Myeloma, Osteolytic Bone Metastases of Solid Tumors, Osteoporosis, Paget's Disease
